Literature DB >> 30290881

Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy.

Jageshwar Prasad Shah1, Yong Yang2, Shijian Chen3, Abdullah Hagar1, Xiao Bo Pu1, Tianli Xia1, Yuanweixiang Ou1, Mao Chen1, Yucheng Chen4.   

Abstract

Few data are available regarding the prevalence and clinical significance of right ventricular systolic dysfunction (RVSD) in hypertrophic cardiomyopathy (HC) patients. This study aimed to evaluate right ventricular (RV) systolic function by cardiovascular magnetic resonance and explore the prevalence and prognostic significance of RVSD in HC patients. A total of 226 patients with HC assessed by cardiovascular magnetic resonance were included in this retrospective study. RVSD was defined by RV ejection fraction (RVEF) ≤45% and was present in 26 (11.5%) patients. Association between RVSD, clinical characteristics, and outcomes were analyzed. RVEF was significantly lower in patients with RVSD than without RVSD (36.2 ± 7.0% vs 60.5 ± 7.4%, p < 0.001). There was a positive correlation between RVEF and left ventricular ejection fraction (r = 0.45; p < 0.001). During a mean follow-up of 30.5 ± 23.9 months, there were 22 (9.7 %) all-cause mortality, including 12 (5.3%) cardiovascular death. Kaplan-Meier analysis showed a significantly higher risk for cardiovascular mortality in patients with RVSD (p = 0.026), but no significant difference in all-cause mortality (p = 0.118) and heart failure related rehospitalization (p = 0.485). On multivariate Cox regression analysis, RVSD (hazard ratio 5.36; confidence interval 1.39 to 20.77; p = 0.015) and RVEF (hazard ratio 0.94; confidence interval 0.89 to 0.98; p = 0.011) were independent predictors of cardiovascular mortality. In conclusion, RVSD is a common phenotype and a strong independent predictor of cardiovascular mortality in HC patients.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30290881     DOI: 10.1016/j.amjcard.2018.08.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample.

Authors:  Emily K Zern; Dongyu Wang; Paula Rambarat; Samuel Bernard; Samantha M Paniagua; Elizabeth E Liu; Jenna McNeill; Jessica K Wang; Carl T Andrews; Eugene V Pomerantsev; Michael H Picard; Jennifer E Ho
Journal:  Circ Heart Fail       Date:  2022-02-09       Impact factor: 8.790

2.  Right ventricular function declines prior to left ventricular ejection fraction in hypertrophic cardiomyopathy.

Authors:  Masliza Mahmod; Betty Raman; Hugh Watkins; Stefan Neubauer; Kenneth Chan; Sanjay Sivalokanathan; Robert W Smillie; Azlan H Abd Samat; Rina Ariga; Sairia Dass; Elizabeth Ormondroyd
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-13       Impact factor: 6.903

3.  Impaired Right Ventricular Mechanics at Rest and During Exercise Are Associated With Exercise Capacity in Patients With Hypertrophic Cardiomyopathy.

Authors:  Xiao-Peng Wu; Yi-Dan Li; Yi-Dan Wang; Miao Zhang; Wei-Wei Zhu; Qi-Zhe Cai; Wei Jiang; Lan-Lan Sun; Xue-Yan Ding; Xiao-Guang Ye; Yun-Yun Qin; Xiu-Zhang Lu
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

4.  Assessing right ventricular deformation in hypertrophic cardiomyopathy patients with preserved right ventricular ejection fraction: a 3.0-T cardiovascular magnetic resonance study.

Authors:  Xiang Li; Ke Shi; Zhi-Gang Yang; Ying-Kun Guo; Shan Huang; Chun-Chao Xia; Sen He; Zhen-Lin Li; Chen Li; Yong He
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

5.  Prevalence, functional characteristics, and clinical significance of right ventricular involvement in patients with hypertrophic cardiomyopathy.

Authors:  Jiwon Seo; Yoo Jin Hong; Young Jin Kim; Purevjargal Lkhagvasuren; Iksung Cho; Chi Young Shim; Jong-Won Ha; Geu-Ru Hong
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.